1
|
Salek R, Bayatmokhtari N, Homaei Shandiz F, ShahidSales S. The Results of Chemotherapy with Two Variants of Intravenous CMF in Patients with Early Stage Breast Carcinoma; Does Dose Density Matter? Breast J 2016; 22:623-629. [PMID: 27540897 DOI: 10.1111/tbj.12652] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
No direct comparisons can be made in early stages of breast cancer, between the intravenous combinations of: cyclophosphamide, methotrexate, and fluorouracil; named modified versions of CMF with the classical oral version of CMF. Since these modifications have different dose intensities and densities, the outcomes for their subsequent treatments may be varied, and not produce the same results. Despite that, classical CMF has been commonly replaced with intravenous modifications. This study aimed to assess the results of treatment with two common intravenous modification of CMF chemotherapy; to represent the most effective and successful substitute of classical CMF. Five hundred patients in two groups were eligible to take part in the experiment. For two hundred and twenty-nine patients in the group CMF 1&8, chemotherapy was administered intravenously on days 1 and 8 every 28 days for six cycles consisting of: cyclophosphamide 600 mg/m2 , methotrexate 40 mg/m2 , fluorouracil 600 mg/m2 . In the group CMF 1 which consisted of 271 patients, chemotherapy was administered with all the same drugs and doses, however, it was only administered on day 1 and repeated at 21-day intervals for six cycles. Overall survival (OS), disease-free survival (DFS), the prognostic factors and other probable interventional factors were then compared between the two groups. The 5-year OS rate of 87.5% and 10-year OS rate of 82% in the group CMF 1&8 were statistically significantly better than 5-year OS of 84% and 10-year OS of 61.5% in the group CMF 1 (p = 0.01). The 5-year and 10-year DFS rates were 76% and 60% respectively, in the group CMF 1&8 compared with 77% and 54% respectively in the group CMF 1 (p = 0.8). Two groups were comparable regarding their distribution of different prognostic factors and other probable interventional factors. Considering 30% higher dose density of drugs in the protocol of CMF 1&8, the improving outcome can be related to the efficacy of dose-dense chemotherapy. Therefore, this intravenous modification is the better substitute of classical CMF.
Collapse
Affiliation(s)
- Roham Salek
- Clinical Radiation Oncology, Faculty of Medicine, Cancer Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
| | - Narges Bayatmokhtari
- Clinical Radiation Oncology, Sabzevar University of Medical Sciences, Mashhad, Iran
| | - Fatemeh Homaei Shandiz
- Clinical Radiation Oncology, Faculty of Medicine, Cancer Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
| | - Soodabeh ShahidSales
- Clinical Radiation Oncology, Faculty of Medicine, Cancer Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
| |
Collapse
|
2
|
Sasse S, Alram M, Müller H, Smardová L, Metzner B, Doehner H, Fischer T, Niederwieser DW, Schmitz N, Schäfer-Eckart K, Raemaekers JMM, Schmalz O, Tresckow BV, Engert A, Borchmann P. Prognostic relevance of DHAP dose-density in relapsed Hodgkin lymphoma: an analysis of the German Hodgkin-Study Group. Leuk Lymphoma 2015; 57:1067-73. [PMID: 26693800 DOI: 10.3109/10428194.2015.1083561] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Only 50% of patients with relapsed Hodgkin lymphoma (HL) can be cured with intensive induction chemotherapy, followed by high-dose chemotherapy (HDCT) and autologous stem cell transplant (ASCT). Based on the results of the HDR2 trial two courses of DHAP and subsequent HDCT/ASCT are the current standard of care in relapsed HL. In order to assess the prognostic relevance of DHAP dose density, we performed a retrospective multivariate analysis of the HDR2 trial (N=266). In addition to four risk factors (early or multiple relapse, stage IV disease or anemia at relapse, and grade IV hematotoxicity during the first cycle of DHAP) a delayed start of the second cycle of DHAP>day 22 predicted a significantly poorer progression-free survival (PFS, p=0.0356) and overall survival (OS, p=0.0025). In conclusion, our analysis strongly suggests that dose density of DHAP has a relevant impact on the outcome of relapsed HL patients.
Collapse
Affiliation(s)
- Stephanie Sasse
- a Internal Medicine I, German Hodgkin Study Group , University Hospital of Cologne , Cologne , Germany
| | - Magdalena Alram
- a Internal Medicine I, German Hodgkin Study Group , University Hospital of Cologne , Cologne , Germany
| | - Horst Müller
- a Internal Medicine I, German Hodgkin Study Group , University Hospital of Cologne , Cologne , Germany
| | - Lenka Smardová
- b University Hospital Brno and Faculty of Medicine , Masaryk University , Brno , Czech Republic
| | - Bernd Metzner
- c Department of Hematology and Oncology , Hospital of Oldenburg , Oldenburg , Germany
| | - Hartmut Doehner
- d Clinic III for Internal Medicine , University Hospital of Ulm , Ulm , Germany
| | - Thomas Fischer
- e Department of Hematology and Oncology , University Hospital of Magdeburg , Magdeburg , Germany
| | - Dietger W Niederwieser
- f Department of Hematology and Oncology , University Hospital of Leipzig , Leipzig , Germany
| | - Norbert Schmitz
- g Department of Hematology, Oncology , Asklepios Clinic St. Georg , Hamburg , Germany
| | | | - John M M Raemaekers
- i Department of Hematology , Radboud University Medical Center , Nijmegen , Netherlands
| | - Oliver Schmalz
- j Clinic I for Internal Medicine , Helios Clinic Wuppertal , Wuppertal , Germany
| | - Bastian V Tresckow
- a Internal Medicine I, German Hodgkin Study Group , University Hospital of Cologne , Cologne , Germany
| | - Andreas Engert
- a Internal Medicine I, German Hodgkin Study Group , University Hospital of Cologne , Cologne , Germany
| | - Peter Borchmann
- a Internal Medicine I, German Hodgkin Study Group , University Hospital of Cologne , Cologne , Germany
| |
Collapse
|
3
|
Wästerlid T, Hartman L, Székely E, Jerkeman M. Impact on survival of addition of etoposide to primary chemotherapy in diffuse large B-cell lymphoma: a Swedish Lymphoma Registry study. Hematol Oncol 2015; 35:151-157. [PMID: 26369736 DOI: 10.1002/hon.2256] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/08/2015] [Revised: 08/12/2015] [Accepted: 08/14/2015] [Indexed: 11/06/2022]
Abstract
No randomised study in the rituximab era has been performed specifically to evaluate addition of etoposide to treatment of diffuse large B-cell lymphoma (DLBCL). The aim of this study was to compare the outcome with three chemotherapy regimens (R-CHOP-21, R-CHOP-14 and R-CHOEP-14) in a population-based cohort in terms of overall survival, adjusted for clinical prognostic factors. Through the Swedish Lymphoma Registry, 3443 patients with DLBCL were identified 2007-2012. Among all patients, there was no evidence of a difference between the regimens, after adjustment for prognostic factors. However, when restricted to patients aged up to 65, R-CHOEP-14 was associated with superior outcome compared to both R-CHOP-21 (hazard ratio: 0.49, 95% confidence interval: 0.3-0.9, p = 0.028) and R-CHOP-14 (hazard ratio: 0.64, 95% confidence interval: 0.4-1.0, p = 0.06), when adjusted for prognostic factors. Results were consistent in an additional stratified analysis with patients grouped according to age and IPI-score. In conclusion, we could show that R-CHOEP-14 was associated with superior overall survival in patients with DLBCL aged up to 65 years, indicating that this may be a valid treatment option for this patient population. To further investigate which patient groups that may benefit the most from treatment intensification, R-CHOEP-14 should be compared to R-CHOP-21 in a randomised setting. Copyright © 2015 John Wiley & Sons, Ltd.
Collapse
Affiliation(s)
- Tove Wästerlid
- Lund University, Department of Clinical Sciences Lund, Department of Oncology, Lund, Sweden
| | - Linda Hartman
- Division of Oncology and Pathology, Department of Clinical Sciences Lund, Lund University, Sweden.,Regional Cancer Centre South, Lund, Sweden
| | - Elisabeth Székely
- Lund University, Department of Clinical Sciences Lund, Department of Oncology, Lund, Sweden
| | - Mats Jerkeman
- Lund University, Department of Clinical Sciences Lund, Department of Oncology, Lund, Sweden
| |
Collapse
|
4
|
Pitz MW, Lipson M, Hosseini B, Lambert P, Guilbert K, Lister D, Schroeder G, Jones K, Mihalicioiu C, Eisenstat DD. Extended adjuvant temozolomide with cis-retinoic acid for adult glioblastoma. ACTA ACUST UNITED AC 2013; 19:308-14. [PMID: 23300356 DOI: 10.3747/co.19.1151] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Abstract
OBJECTIVE To determine the toxicity and effectiveness of 24 months of adjuvant temozolomide (tmz) with cis-retinoic acid (cra) for patients with glioblastoma. METHODS This retrospective population-based review considered the charts of all patients diagnosed with glioblastoma in Manitoba and referred to a provincial cancer centre during 2002-2008. Consecutive patients came from a population-based referral centre and provincial cancer registry. All patients were treated according to the local standard of care with surgical resection followed by concurrent radiotherapy and tmz 75 mg/m(2) daily, followed by tmz 150-200 mg/m(2) for days 1-5, repeated every 28 days for up to 24 cycles, and cra 50 mg/m(2) twice daily for days 1-21, repeated every 28 days. The main outcome measures were safety, tolerability, and effectiveness of long-term tmz and cra. RESULTS Of 247 patients diagnosed with glioblastoma in Manitoba during the study period, 116 started concurrent chemoradiotherapy, and 80 received adjuvant tmz. Of the patients who started concurrent chemoradiotherapy, 80 began adjuvant chemotherapy. Patients completed a median of 5.5 cycles of tmz and 3 cycles of cra. Grade 3 or 4 hematologic toxicity was noted in 16% of patients. Median overall survival was 15.1 months, and 26.7% of patients remained alive at 2 years. CONCLUSIONS Extended adjuvant tmz and cra is well tolerated. However, the population-based effectiveness of this regimen is similar to the clinical trial efficacy of 6 months of adjuvant tmz. Future studies in glioblastoma should incorporate duration of adjuvant chemotherapy into the study design.
Collapse
Affiliation(s)
- M W Pitz
- Department of Internal Medicine, University of Manitoba, Winnipeg, MB. ; Department of Haematology/Medical Oncology, CancerCare Manitoba, Winnipeg, MB
| | | | | | | | | | | | | | | | | | | |
Collapse
|